USANA Health Sciences (USNA) News Today

USANA Health Sciences, Inc. (NYSE: USNA) — Shares are trading lower after the company reported mixed third-quarter results and received a fresh analyst downgrade. Below are the key items driving the move and what investors should watch next.

• Positive Sentiment: Company raised full‑year FY2025 guidance slightly above Street expectations — EPS guidance of 1.73 and revenue guidance of about $920.0M, nudging ahead of consensus. This provides some support that management sees recovery later in the year. USANA FY2025 Guidance
• Positive Sentiment: Top‑line improvement: Q3 net sales rose ~7% year‑over‑year to $214M, showing continuing revenue traction despite profitability weakness. Q3 Sales Increase
• Neutral Sentiment: Analyst/preview coverage and context pieces are available ahead of/after the print for additional detail on drivers and regionals trends. Investors may use these to dig into channel and margin assumptions. Earnings Preview
• Negative Sentiment: Material earnings miss and profitability deterioration: USNA reported adjusted EPS loss (adjusted diluted EPS -$0.15; GAAP diluted EPS -$0.36) and revenue below consensus ($214M vs. ~$225M expected), swinging from prior‑year profitability to a Q3 net loss — a primary driver of the negative price reaction. Q3 Results Press Release
• Negative Sentiment: Analyst downgrade: Zacks Research lowered USNA from “hold” to “strong sell,” adding near‑term selling pressure and signaling lowered confidence in the recovery path. Zacks Downgrade

Investor takeaway: revenue growth is a positive sign, but the EPS miss, return to a net loss and the Zacks downgrade are weighing on sentiment. Watch upcoming quarterly cadence, margin recovery, and whether guidance holds in coming quarters for signs of stabilization.